

Kara Levinson, PhD, MPH, D(ABMM), Director
Nashville Central Laboratory
630 Hart Lane
Nashville, TN 37243
615-262-6300

Kara Levinson, PhD, MPH, D(ABMM), Interim Director
Knoxville Regional Laboratory
2101 Medical Center Way
Knoxville, TN 37920
865-549-5201

Date Reported: 7/23/2024

PRELIMINARY REPORT

Page 1 of 3

Patient Name: **TEST1, TEST**
Sex: **M**
Patient ID:
Medical Record No.:
Specimen Type: **Abscess**
Specimen Source:
Date Collected: **07/23/2024**
Date Received: **07/23/2024**
Date of Onset:

Accession #: **N24E001124-01**
Date of Birth: **07/23/2024**
Race:
Ethnicity:
Facility:
**Tennessee Dept of Health Lab Services -
Nashville
630 Hart Lane
Nashville, TN 37247**
Ordering Provider:

County:
Region:
Patient Address:
, TN
Event ID:

Carbapenem Resistant Organism Culture

Key:
S=Susceptible
I=Intermediate
R=Resistant

RESULT: Carbapenem Resistant Organism Culture *Enterobacter cloacae*

BMD

Enterobacter cloacae

				Reference Range			Location
Drug	Interpretation	Results	Units	S	I	R	
Amikacin	Resistant	16	ug/mL	16	32	> 32	NASHVILLE
Ampicillin	Resistant	> 16	ug/mL	8	16	> 16	NASHVILLE
Ampicillin+sulbactam	Resistant	> 16/8	ug/mL	8/4	16/8	>16/8	NASHVILLE
Aztreonam	Resistant	> 16	ug/mL	4	8	16	NASHVILLE
Cefazolin	Resistant	> 16	ug/mL	2	4	8	NASHVILLE
Cefepime	Resistant	> 16	ug/mL	2	4	16	NASHVILLE
Ceftazidime	Resistant	> 16	ug/mL	4	8	16	NASHVILLE
Ceftazidime+avibactam	Resistant	> 16/4	ug/mL	8/4		16/4	NASHVILLE
Ceftolozane+tazobactam	Resistant	> 16/4	ug/mL	2/4	4/4	8/4	NASHVILLE
Ceftriaxone	Resistant	32	ug/mL	1	2	4	NASHVILLE

ATTN: Paula Gibbs
Tennessee Dept of Health Lab Services - Nashville
630 Hart Lane
Nashville, TN 37247



Kara Levinson, PhD, MPH, D(ABMM), Director
Nashville Central Laboratory
630 Hart Lane
Nashville, TN 37243
615-262-6300

Kara Levinson, PhD, MPH, D(ABMM), Interim Director
Knoxville Regional Laboratory
2101 Medical Center Way
Knoxville, TN 37920
865-549-5201

Date Reported: 7/23/2024

PRELIMINARY REPORT

Page 2 of 3

Accession #: **N24E001124-01**

Date of Birth: **07/23/2024**

Patient Name: **TEST1, TEST**

Enterobacter cloacae

Ciprofloxacin	Resistant	> 2	ug/mL	0.25	0.5	1	NASHVILLE
Doripenem	Resistant	> 4	ug/mL	1	2	4	NASHVILLE
Ertapenem	Resistant	> 8	ug/mL	0.5	1	2	NASHVILLE
Gentamicin	Resistant	> 8	ug/mL	4	8	> 8	NASHVILLE
Imipenem	Resistant	> 8	ug/mL	1	2	4	NASHVILLE
Levofloxacin	Resistant	> 8	ug/mL	< 1	1	2	NASHVILLE
Meropenem	Resistant	> 8	ug/mL	1	2	4	NASHVILLE
Minocycline	Resistant	> 8	ug/mL	4	8	>8	NASHVILLE
Nitrofurantoin	Resistant	> 64	ug/mL	32	64	>64	NASHVILLE
Piperacillin+Tazobactam	Resistant	> 64/4	ug/mL	8/4	16/4	32/4	NASHVILLE
Tetracycline	Resistant	> 8	ug/mL	4	8	> 8	NASHVILLE
Tigecycline	Resistant	> 8	ug/mL				NASHVILLE
Tobramycin	Resistant	> 8	ug/mL	4	8	> 8	NASHVILLE
Trimethoprim+Sulfamethoxazole	Resistant	> 2/38	ug/mL	< 2/38		> 2/38	NASHVILLE

mCIM

Carbapenemase
Production

Positive

NASHVILLE

ATTN: Paula Gibbs
Tennessee Dept of Health Lab Services - Nashville
630 Hart Lane
Nashville, TN 37247



Kara Levinson, PhD, MPH, D(ABMM), Director
Nashville Central Laboratory
630 Hart Lane
Nashville, TN 37243
615-262-6300

Kara Levinson, PhD, MPH, D(ABMM), Interim Director
Knoxville Regional Laboratory
2101 Medical Center Way
Knoxville, TN 37920
865-549-5201

Date Reported: 7/23/2024

PRELIMINARY REPORT

Page 3 of 3

Accession #: **N24E001124-01**

Date of Birth: **07/23/2024**

Patient Name: **TEST1, TEST**

	RESULTS	Reference Range	Performing Location
<u>Streck ARM-D RT-PCR β-lactamase</u>			
IMP	Not Detected	Not Detected	NASHVILLE
KPC	Not Detected	Not Detected	NASHVILLE
OXA-48	Not Detected	Not Detected	NASHVILLE
VIM	Not Detected	Not Detected	NASHVILLE
NDM	Detected	Not Detected	NASHVILLE

Comments:

MALDI-TOF Mass Spectrometry was utilized as part of the identification process of this isolate. Performance characteristics of this test were determined by Tennessee Department of Health Laboratory Services. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Breakpoints when cefazolin is used for therapy of infections other than uncomplicated UTIs due to *E. coli*, *K. pneumoniae*, and *P. mirabilis*. Breakpoints are based on a dosage regimen of 2 g administered every 8 h.

The cefepime breakpoint for SDD is based on dosage regimens that result in higher cefepime exposure, either higher doses or more frequent doses, or both, up to approved maximum dosing regimens.

Piperacillin/tazobactam breakpoints for SDD are based on a dosage regimen of 4.5g administered every 6h as a 3-h infusion or 4.5g administered every 8h as a 4-h infusion.

Disclaimer:

The GN7F BMD panel performance characteristics have been determined by the TDH Division of Laboratory Services. It has not been cleared or approved by the U.S. Food and Drug Administration.

FDA interpretive guidelines were used for Tigecycline breakpoints.

The performance characteristics of the Streck ARM-D β -lactamase real-time PCR test were validated by TDH Laboratory Services. This test has not been cleared or approved by the U.S. Food and Drug Administration.

ATTN: Paula Gibbs
Tennessee Dept of Health Lab Services - Nashville
630 Hart Lane
Nashville, TN 37247